Employee warrant grants at Ascendis Pharma (NASDAQ: ASND)

Rhea-AI Filing Summary

Ascendis Pharma A/S reported that its board granted an aggregate of 32,310 warrants to certain employees under Appendix 1a to its Articles of Association. Each warrant gives the right to subscribe for one ordinary share at an exercise price of US $249.84 per share, matching the closing price of the company’s American Depositary Shares on the grant date.

Subject to earlier vesting upon certain exit events and continued service, 25% of the warrants will vest one year after the grant date, while the remaining 75% will vest in equal monthly installments over the following 36 months. After this grant, warrants to subscribe for an additional 1,611,843 shares remain available for future grants under the Articles of Association.

Key Figures

Warrants granted: 32,310 warrants Exercise price: US $249.84 per share Initial vesting portion: 25% of warrants +2 more

5 metrics

Warrants granted 32,310 warrants Aggregate employee grant on April 14, 2026

Exercise price US $249.84 per share Equal to ADS closing price on grant date

Initial vesting portion 25% of warrants Vests one year after grant, subject to conditions

Monthly vesting portion 75% of warrants Vests 1/36th per month after first year

Remaining warrant pool 1,611,843 warrants Available for future grants after this issuance

Key Terms

warrants, American Depositary Shares, Articles of Association, ordinary share, +1 more

5 terms

warrants financial

"granted an aggregate of 32,310 warrants to certain employees of the Company"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

American Depositary Shares financial

"the closing price of the American Depositary Shares (“ADS”) representing the Company’s ordinary shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Articles of Association regulatory

"under the terms of Appendix 1a to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

ordinary share financial

"Each Warrant confers the right to subscribe for one ordinary share of the Company"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

exit events financial

"Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On April 14, 2026, the Company’s board of directors granted an aggregate of 32,310 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $249.84 per share, the closing price of the American Depositary Shares (“ADS”) representing the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,611,843 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: April 15, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma (ASND) disclose in this Form 6-K?

Ascendis Pharma disclosed that its board granted 32,310 employee warrants, each exercisable for one ordinary share. The filing also notes an exercise price of US $249.84 per share and confirms remaining warrant capacity under the company’s Articles of Association.

How many warrants did Ascendis Pharma (ASND) grant and to whom?

The company granted an aggregate of 32,310 warrants to certain employees. Each warrant allows the holder to subscribe for one ordinary share, providing equity-based compensation aligned with the company’s existing warrant framework under Appendix 1a to its Articles of Association.

What is the exercise price of the new Ascendis Pharma (ASND) warrants?

Each new warrant has an exercise price of US $249.84 per share. This price equals the closing price of Ascendis Pharma’s American Depositary Shares on the grant date, directly linking employee warrant pricing to the market value at that time.

How do the Ascendis Pharma (ASND) warrants vest over time?

Subject to continued service and possible earlier vesting upon certain exit events, 25% of the warrants vest one year after grant. The remaining 75% then vest at a rate of 1/36th per month over the following three years, creating a four-year total vesting horizon.

How many additional warrants can Ascendis Pharma (ASND) still grant?

After this grant, warrants to subscribe for an additional 1,611,843 shares remain available. These may be granted in the future by the board of directors pursuant to the company’s Articles of Association, continuing its equity-based incentive capacity.

Are the new Ascendis Pharma (ASND) warrants linked to American Depositary Shares?

Each warrant entitles the holder to subscribe for one ordinary share, and the exercise price was set using the closing price of the American Depositary Shares on the grant date, connecting the warrant economics to the ADS market valuation.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 1.2 MB